|
HER2 is a minority, different from general bc
It is more spendy and probably is more stressful to monitor more closely, but once again -- what might be true in terms of monitoring for "average" bc is less likely to be true for HER2. There probably IS a risk benefit ratio for us for monitoring frequency as well, and it may even vary somewhat depending on stage, but it should be more frequent than the guidelines for general bc because HER2 grows faster.
And even if actual outcome in some cases might not end up being any different, why would we want to be left to unknowingly continue on difficult treatments if we are kept in the dark longer about progression? In addition, people with limited resources may choose to allocate them very differently if they know they have progression sooner.
I'm not an oncologist, but even I have that much common sense.
AlaskaAngel
|